Product Information
LORYNA 3 MG-0.02 MG TABLET is a generic product labeled by Xiromed LLC, priced at $0.1909 per EA under NDC 70700011485. Its NADAC has been published 425 times since Aug 15, 2018.
FDA first approved this application on Mar 28, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Xiromed LLCNDC
70700011485
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA079221FDA Approved
3/28/2011
TE Code
AB
On Market Since
6/9/2022
Price Statistics
The NADAC for LORYNA 3 MG-0.02 MG TABLET has been published 425 times since Aug 15, 2018, and over the history we have for it it has declined 72.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1909 per EA |
|---|---|
| All-time high | $0.6994 (Aug 15, 2018) |
| All-time low | $0.1278 (Nov 20, 2024) |
| 52-week high | $0.1933 |
| 52-week low | $0.1538 |
| Median price | $0.3301 |
| Average price | $0.3147 |
| Largest weekly change | -32.1% (Nov 20, 2024) |
| Weeks tracked | 425 |
| Tracking since | Aug 15, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Drospirenone and Ethinyl Estradiol Tablets market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xiromed LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Drospirenone and Ethinyl Estradiol Tablets market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LORYNA 3 MG-0.02 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LORYNA 3 MG-0.02 MG TABLET, manufactured by Xiromed LLC, is $0.1909 per EA (NDC 70700011485), effective Sep 30, 2026.
How has the price of LORYNA 3 MG-0.02 MG TABLET changed over time?
Over the history we have for it, the NADAC for LORYNA 3 MG-0.02 MG TABLET has declined 72.7%. It has been tracked across 425 weekly CMS publications since Aug 15, 2018.
What are the highest and lowest recorded NADAC prices for LORYNA 3 MG-0.02 MG TABLET?
Since Aug 15, 2018, the NADAC for LORYNA 3 MG-0.02 MG TABLET has ranged from a low of $0.1278 (Nov 20, 2024) to a high of $0.6994 (Aug 15, 2018), with a median of $0.3301 per EA.
Are there cheaper alternatives to LORYNA 3 MG-0.02 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LORYNA 3 MG-0.02 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LORYNA 3 MG-0.02 MG TABLET?
LORYNA 3 MG-0.02 MG TABLET (NDC 70700011485) is labeled by Xiromed LLC, and CMS classifies it as a generic product.